লোডিং...

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to LDL receptors, leading to their degradation. Genetics studies have shown that loss-of-function mutations in PCSK9 result in reduced plasma LDL cholesterol and decreased risk of coronary heart disease. We aimed to investigate...

সম্পূর্ণ বিবরণ

সংরক্ষণ করুন:

গ্রন্থ-পঞ্জীর বিবরন
প্রকাশিত:	Lancet
প্রধান লেখক:	Fitzgerald, Kevin, Frank-Kamenetsky, Maria, Shulga-Morskaya, Svetlana, Liebow, Abigail, Bettencourt, Brian R, Sutherland, Jessica E, Hutabarat, Renta M, Clausen, Valerie A, Karsten, Verena, Cehelsky, Jeffrey, Nochur, Saraswathy V, Kotelianski, Victor, Horton, Jay, Mant, Timothy, Chiesa, Joseph, Ritter, James, Munisamy, Malathy, Vaishnaw, Akshay K, Gollob, Jared A, Simon, Amy
বিন্যাস:	Artigo
ভাষা:	Inglês
প্রকাশিত:	2013
বিষয়গুলি:	Article
অনলাইন ব্যবহার করুন:	https://ncbi.nlm.nih.gov/pmc/articles/PMC4387547/ https://ncbi.nlm.nih.gov/pubmed/24094767 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(13)61914-5
ট্যাগগুলো:	ট্যাগ যুক্ত করুন কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

অনুরূপ উপাদানগুলি